A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 5, 2013, Pages 287-297

  Baranidharan, Ganesan ^a   Das, Sangeeta ^a   Bhaskar, Arun ^b  

^a SEACROFT HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Capsaicin; efficacy; high concentration patch; HIV; neuropathic pain; post herpetic neauralgia

Indexed keywords

CAPSAICIN; MORPHINE; PREGABALIN;

ANALGESIA; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; BRIEF PAIN INVENTORY; COUGHING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TRANSDERMAL PATCH;

EID: 84883382849     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285613496862     Document Type: Article

References (29)

1. Alawi K. Keeble J. (2010) The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther 125: 181–195.
2. Anand P. Bley K. (2011) Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 107: 490–502.
3. Astellas Pharma Europe Ltd. (2012) Tolerability of QUTENZATM when Applied after Pre-treatment with Lidocaine or Tramadol in Subjects with Peripheral Neuropathic Pain – A Randomized, Multi-center, Assessor-blinded Study. Chertsey, UK.
4. Babbar S. Marier J. Mouksassi M. Beliveau M. Vanhove G. Chanda S. et al. (2009) Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit 31: 502–510.
5. Backonja M. Irving A. Webster R. (2009) Efficacy of Qutenza_ (NGX-4010), a high concentration capsaicin cutaneous patch, in patients with peripheral neuropathic pain: results of integrated analyses. Eur J Neurol 3: 1046.
6. Backonja M. Malan T. Vanhove G. Tobias J. ; C102/106 Study Group. (2010) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 11: 600–608.
7. Backonja M. Wallace M. Blonsky E. Cutler B. Malan P. Rauck R. et al. (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7: 1106–1112.
8. Bhaskar A. England J. Lowe J. (2012) Management of neuropathic pain (NP) using the capsaicin 8% patch in patients with cancer. Presented at the European Association for Palliative Care, Norway. Poster 465.
9. Bode A. Dong Z. (2011) The two faces of capsaicin. Cancer Res 71: 2809–2814.
10. Chaiyasit K. Khovidhunkit W. Wittayalertpanya S. (2009) Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai 92: 108–113.
11. Chard P. Bleakman D. Savidge J. Miller R. (1995) Capsaicin-induced neurotoxicity in cultured dorsal root ganglion neurons: involvement of calcium-activated proteases. Neuroscience 65: 1099–1108.
12. Clifford D. Simpson D. Brown S. Moyle G. Brew B. Conway B. (2010) A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco.
13. Derry S. Moore R. (2012) Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 9: CD010111.
14. Derry S. Sven-Rice A. Cole P. Tan T. Moore R. (2013) Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2: CD007393.
15. European Medicines Agency. (2013) Summary of Product Characteristics: Qutenza 179 mg cutaneous patch. [http://tinyurl.com/4y9hahb.
16. FDA Center for Drug Evaluation and Research (2009) Medical Review: Qutenza. Silver Spring, MD. [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022395s000Medr.pdf]
17. Han P. McDonald H. Bianchi B. Kouhen R. Vos M. Jarvis M. et al. (2007) Capsaicin causes protein synthesis inhibition and microtubule disassembly through TRPV 1 activities both on the plasma membrane and intracellular membranes. Biochem Pharmacol 73: 1635–1645.
18. Irving G. Backonja M. Dunteman E. Blonsky E. Vanhove G. Lu S. et al. (2010) A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 12: 99–109.
19. Jensen T. Madsen C. Finnerup N. (2009) Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22: 467–474.
20. Luo X. Peng J. Li Y. (2011) Recent advances in the study on capsaicinoids and capsinoids. Eur J Pharmacol 650: 1–7.
21. Martindale W. (1999) Ed. Reynolds J. (ed.), The Extra Pharmacopoeia/Martindale, 32nd edition. London: The Pharmaceutical Press.
22. McCormack P. (2010) Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain. Drugs 70: 1831–1842.
23. Polydefkis M. Hauer P. Sheth S. Sirdofsky M. Griffin J. McArthur J. (2004) The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 127: 1606–1615.
24. Shimomura Y. Kawada T. Suzuki M. (1989) Capsaicin and its analogs inhibit the activity of NADH-coenzyme Q oxidoreductase of the mitochondrial respiratory chain. Arch Biochem Biophys 270: 573–577.
25. Simpson D. Brown S. Tobias J. ; NGX-4010 C 107 Study Group. (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70: 2305–2313.
26. Simpson D. Gazda S. Brown S. Webster L. Lu S. Tobias J. et al. (2010) Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 39: 1053–1064.
27. Thresh J. (1876) Isolation of capsaicin. The Pharmaceutical Journal and Transactions 6: 941–947.
28. Turnbull A. (1850) Tincture of capsaicin as a remedy for chilblains and toothache. Dublin Free Press 1: 95–96.
29. Webster L. Malan T. Tuchman M. Mollen M. Tobias J. Vanhove G. (2010) A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 11: 972–982.